Bao Thu Nguyen, MD
Ophthalmology · Long Beach, CANPI 1538137666
Payments from drug & device makers
Across 844 payments — averaging $119.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$82K
- AbbVie$5K
- Aerie Pharmaceuticals, Inc.$3K
- Alcon$2K
- Bausch & Lomb Americas Inc.$1K
- Sun Pharmaceutical Industries Inc.$1K
- plus $6K from 26 others
Across 1 payment — averaging $239.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$239
What the payments were for
- Consulting fees$1,3206%
- Speaking & faculty fees$1,1105%
- Grants$2,40011%
- Food & beverage$17,72278%
- Education$890%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 83 | $82,241 |
| AbbVie(2 entities) | 238 | $5,148 |
| Aerie Pharmaceuticals, Inc. | 83 | $2,658 |
| Alcon | 77 | $2,109 |
| Bausch & Lomb Americas Inc. | 74 | $1,491 |
| Sun Pharmaceutical Industries Inc. | 56 | $1,186 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 44 | $737 |
| Amgen(2 entities) | 22 | $545 |
| Nova Eye, Inc. | 2 | $539 |
| Sight Sciences, Inc. | 23 | $525 |
| Mallinckrodt Hospital Products Inc. | 23 | $512 |
| Tarsus Pharmaceuticals, Inc. | 15 | $478 |
| ANI Pharmaceuticals, Inc. | 22 | $333 |
| Oyster Point Pharma, Inc. | 12 | $271 |
| Kala Pharmaceuticals, Inc. | 15 | $263 |
| Novartis | 12 | $236 |
| Beaver-visitec International, Inc. | 3 | $211 |
| Dompe US, Inc. | 8 | $207 |
| Eyevance Pharmaceuticals LLC | 6 | $129 |
| Biotissue Holdings Inc. | 1 | $124 |
| Apellis Pharmaceuticals, Inc. | 1 | $123 |
| Harrow Eye, LLC | 4 | $120 |
| Thea Pharma Inc. | 6 | $119 |
| Shire North American Group Inc | 4 | $75 |
| Optovue, Inc. | 1 | $50 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $40 |
| Ocular Therapeutix, Inc. | 3 | $40 |
| Boston Scientific | 1 | $30 |
| Grifols USA, LLC | 1 | $25 |
| Rayner Intraocular Lenses Limited | 1 | $24 |
| Rxsight Inc | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent inject Trabecular Micro-Bypass Stent System$2,400
- Rhopressa$1,557
- Rocklatan$1,557
- DURYSTA$528
- MIEBO$253
- XIIDRA$253
- Hydrus Microstent$249
- XEN GLAUCOMA TREATMENT SYSTEM$168
- TEPEZZA$150
- OMNI(R) SURGICAL SYSTEM (US)$141
- iStent Trabecular Micro-Bypass Stent System$131
- Photrexa$129
- iStent Infinite$128
- iDoseTR$128
- VYZULTA$128
- Wavelight$120
- Clareon$113
How this compares
$100,633 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 507 | $304,405 |
| RestasisCyclosporine | 268 | $268,152 |
| VyzultaLatanoprostene Bunod | 478 | $250,164 |
| RocklatanNetarsudil Mesylat/Latanoprost | 173 | $107,990 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 324 | $96,850 |
| RhopressaNetarsudil Mesylate | 165 | $88,614 |
| Alphagan PBrimonidine Tartrate | 146 | $70,950 |
| XiidraLifitegrast | 65 | $67,163 |
| CombiganBrimonidine Tartrate/Timolol | 152 | $66,872 |
| MieboPerfluorohexyloctane/Pf | 52 | $59,635 |
| Cyclosporine | 109 | $53,469 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 129 | $25,547 |
| Lotemax SmLoteprednol Etabonate | 73 | $18,927 |
| ProlensaBromfenac Sodium | 49 | $18,086 |
| TyrvayaVarenicline Tartrate | 27 | $17,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $5,148 | $710,3781,073 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $1,491 | $376,962595 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $2,658 | $196,604338 claims |
| AlconSimbrinza | $2,109 | $96,850324 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Loteprednol Etabonate, Lotemax, Besivance | $737 | $50,423188 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $271 | $17,70827 claims |
| NovartisTravatan Z, Ilevro | $236 | $14,53327 claims |
| Thea Pharma Inc.Iyuzeh | $119 | $12,32525 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,186 | $10,75811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Long Beach
- Julie GasperiniLong Beach$814K
- Carl HartmanLong Beach$716K
- Dan TranLong Beach$649K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.